|
< Back
to Newsroom
|
MultiCell Technologies' Proprietary
Breakthrough Anti-Cancer Therapy Shown to Prevent Recurrence of Cancer
Company's MCT-465 Drug Combined with Patented
Immune-System Modulation Technology Prevents New Tumor Growth in
Preclinical Animal Model
SAN
DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), developing
first-in-class drugs based on advanced immune system modulation
technologies, has announced that the Company's proprietary anti-cancer technologies
not only eradicated cancer in animal studies but also prevented the
recurrence of the disease.
The research focused on
a unique combination therapy based on MCET's MCT-465 drug candidate
co-administered with IgNP, a proprietary MCET immune-modulation drug. It
found that the Company's combination therapy not only destroyed cancerous
tumors but conferred protection against new tumor growth, or recurrence of
the disease.
"In cancer
treatment, destroying the tumor is half the battle, while the other half is
preventing the cancer from recurring," said Dr. Stephen Chang, Chief
Executive Officer of MultiCell Technologies. "These findings are
important because they demonstrate that our drug can prevent the cancer
from returning. Preventing cancer from recurring in animal models is an
important benchmark in developing new cancer therapeutics and toward
prolonging life."
Specifically, the
research examined the co-administration of MCT-465, a Toll-like Receptor
(TLR) agonist and IgNP, the Company's patented antigen presenting
immunoglobulin therapeutic.
"Previously we
demonstrated conclusively that co-administration of MCT-465 with our
patented antigen-presenting immunoglobulin therapeutic ('IgNP') completely
destroyed tumors and prevented mortality," said Dr. Chang. "Now
we have demonstrated that this same therapy prevents the recurrence of
secondary cancers in animal models. Additionally, the T-cells from the
immunized mice displayed a long-lasting, increased production of certain
cytokines which are key players in the destruction of tumors."
The Company's scientists
demonstrated that mice previously treated with the IgNP/MCT-465 combination
therapy which demonstrated tumor remission, remained immune to the
development of new cancers even when challenged with a new tumorigenic dose
of homologous tumor cells. The challenged mice were completely protected
against secondary cancers, whereas the control group of mice developed
tumors with a 100% rate.
"Our work in this
area was recently published in the Journal of Immunology, and we have filed
several patents covering the technology," noted Dr. Chang.
MultiCell is an
innovator in the science of modulating the human immune system with unique
platform technologies, focusing on the development of breakthrough drugs to
treat serious diseases, including multiple sclerosis, type-1 diabetes,
influenza, and cancer.
About MultiCell
Technologies, Inc.
MultiCell Technologies,
Inc. is an integrated biopharmaceutical company committed to the
development of breakthrough therapeutics based on a portfolio of
therapeutic candidates and patented drug development technology.
MultiCell's drug development program is focused on modulation of the immune
system.
MultiCell's therapeutic
pipeline includes drug candidates, some of which are in various advanced
stages of human clinical trials. These therapies include:
- MCT-125 for the treatment of
chronic fatigue in MS patients. MCT-125 completed a Phase II clinical
trial and demonstrated significant efficacy in reducing chronic
fatigue in MS patients. There is no drug specifically approved for the
treatment of chronic fatigue in MS patients anywhere in the world.
- MCT-175 for the treatment of
relapsing-remitting MS. MCT-175, in preclinical development for the
treatment of relapsing-remitting MS, targets disease specific
autoaggressive T-cells that destroy the myelin sheath of nerve cells.
MCT-175 successfully ameliorated the disease in animal models.
- MCT-275 for the treatment of
type-1 diabetes. MCT-275, in preclinical development, targets
disease-specific autoaggressive T-cells that destroy insulin producing
cells in the pancreas. MCT-275 completely reversed the type-1 diabetic
phenotype and prolonged life in animal models.
- MCT-465 in an adjuvant therapy
for the treatment of virus infection and cancer. MCT-465 in
preclinical studies successfully reduced pulmonary influenza virus
levels 1,000-fold in animal models, and has demonstrated effectiveness
in reducing virus levels of HIV and HCV in animal models. MCT-465 in
preclinical studies successfully eliminated certain types of tumors in
animal models.
The Company also holds
unique cell-based technology for use in drug discovery screening
applications, and is a leading producer of the cell lines needed by the
biotechnology industry to develop new drugs. For more information about
MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding
Forward-Looking Statements
Any statements in this
press release about MultiCell's expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and
are forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"). These statements are
often, but not always, made through the use of words or phrases such as
"believe," "will," "expect," "anticipate,"
"estimate," "intend," "plan," "forecast,"
"could," and "would." Examples of such forward looking
statements include statements regarding the timing, design, scope, and
anticipated results of our clinical development of MCT-465. MultiCell bases
these forward-looking statements on current expectations about future
events. They involve known and unknown risks, uncertainties and assumptions
that may cause actual results, levels of activity, performance or
achievements to differ materially from those expressed or implied by any
forward-looking statement. Some of the risks, uncertainties and assumptions
that could cause actual results to differ materially from estimates or
projections in the forward-looking statement include, but are not limited
to, the risk that we might not achieve our anticipated clinical development
milestones, receive regulatory approval, or successfully commercialize
MCT-465 as expected, the market for our products will not grow as expected,
and the risk that our products will not achieve expectations. For
additional information about risks and uncertainties MultiCell faces, see
documents MultiCell files with the SEC, including MultiCell's report on
Form 10-KSB for the fiscal year ended November 30,
2005,
and all our quarterly and other periodic SEC filings. MultiCell claims the
protection of the safe harbor for forward-looking statements under the Act
and assumes no obligation and expressly disclaim any duty to update any
forward-looking statement to reflect events or circumstances after the date
of this news release or to reflect the occurrence of subsequent events.
Contact:
MultiCell Technologies, Inc.
Dr. Stephen Chang, 858.200.0598
MCETInvestor@MultiCelltech.com
or
SmallcapInsights.com
Dr. John Faessel, 858-587-8590
editors@smallcapinsights.com
or
Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.com
Source: Business Wire (Thursday January 11, 6:30 am ET)
|
